Drug Resistance in the Microaerophilic Parasite Giardia lamblia

Current Tropical Medicine Reports

Volumn 2, Issue 3, 2015, Pages 128-135

  Leitsch, David ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Chemotherapy; Drug resistance; Dysentery; Giardia lamblia

Indexed keywords

ALBENDAZOLE; BACITRACIN; FURAZOLIDONE; MEPACRINE; METRONIDAZOLE; NITAZOXANIDE; ORNIDAZOLE; PAROMOMYCIN; TINIDAZOLE;

CHEMOTHERAPY; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG RESISTANCE; GIARDIA INTESTINALIS; GIARDIASIS; MALABSORPTION; NAUSEA; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 84973298662     PISSN: None     EISSN: 21963045     Source Type: Journal    
DOI: 10.1007/s40475-015-0051-1     Document Type: Review

References (91)

1. Buret AG. Pathophysiology of enteric infections with Giardia duodenalis. Parasite. 2008;15:261–5.
2. Farthing MJ. Giardiasis. J Pediatr Gastroenterol Nutr. 1997;24:79–88.
3. Halliez MC, Buret AG. Extra-intestinal and long term consequences of Giardia duodenalis infections. World J Gastroenterol. 2013;19:8974–85.
4. Centers for Disease Control and Prevention. Parasites—Giardia. http://www.cdc.gov/parasites/giardia. Accessed April 10 2015.
5. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J, et al. Auranofin, a reprofiled drug, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother. 2013;57:2029–35. Description of auranofin as a promising novel antigiardial drug.
6. Kulakova L, Galkin A, Chen CZ, Southall N, Marugan JJ, Zheng W, et al. Discovery of novel antigiardiasis drug candidates. Antimicrob Agents Chemother. 2014;58:7303–11. Description of fumagillin as a promising novel antigiardial drug.
7. Tejman-Yarden N, Eckman L. New approaches to the treatment of giardiasis. Curr Opin Infect Dis. 2011;24:451–6.
8. Mørch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic characterisation of parasites in refractory giardiasis after an outbreak in Norway. J Infect Dis. 2008;56:268–73.
9. Nash TE. Treatment of Giardia lamblia infections. Pediatr Infect Dis J. 2001;20:193–5.
10. Wensaas KA, Langeland N, Rortveit G. Prevalence of recurring symptoms after infection with Giardia lamblia in a non-endemic area. Scand J Prim Health. 2009;27:12–7.
11. Bell CA, Cory M, Fairley TA, Hall JE, Tidwell RR. Structure-activity relationships of pentamidine analogs against Giardia lamblia and correlation of antigiardial activity with DNA-binding affinity. Antimicrob Agents Chemother. 1991;35:1099–107.
12. Escobedo AA, Cimerman S. Giardiasis: a pharmacotherapy review. Expert Opin Pharmacother. 2007;8:1885–902.
13. Cosar C, Julou L. The activity of 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (R. P. 8823) against experimental Trichomonas vaginalis infections. Ann Inst Pasteur (Paris). 1959;96:238–41.
14. Schneider J. Treatment of giardiasis (lambliasis) by metronidazole. Bull Soc Pathol Exot Filiales. 1961;54:84–95.
15. Upcroft P, Upcroft JA. Drug targets and mechanisms of resistance in the anaerobic protozoa. Clin Microbiol Rev. 2001;14:150–64.
16. Yarlett N, Gorell TE, Marczak R, Müller M. Reduction of nitroimidazole derivatives by hydrogenosomal extracts of Trichomonas vaginalis. Mol Biochem Parasitol. 1985;14:29–40.
17. Samuelson J. Why metronidazole is active against both bacteria and parasites. Antimicrob Agents Chemother. 1999;43:1533–41.
18. Centers for Disease Control and Prevention. Report on carcinogens, 13th edition. Metronidazole. http://ntp.niehs.nih.gov/ntp/roc/content/profiles/metronidazole.pdf. Accessed April 10th 2015.
19. Edwards DI. Nitroimidazole drugs—action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother. 1993;31:9–20.
20. Uzlikova M, Nohynkova E. The effect of metronidazole on the cell cycle and DNA in metronidazole-susceptible and -resistant Giardia cell lines. Mol Biochem Parasitol. 2014;198:75–81. This study proves that metronidazole damages DNA in Giardia.
21. Leitsch D, Kolarich D, Wilson IBH, Altmann F, Duchêne M. Nitroimidazole action in Entamoeba histolytica: a central role for thioredoxin reductase. PLoS Biol. 2007;5:1820–34.
22. Leitsch D, Kolarich D, Binder M, Stadlmann J, Altmann F, Duchêne M. Trichomonas vaginalis: metronidazole and other nitroimidazole drugs are reduced by the flavin enzyme thioredoxin reductase and disrupt the cellular redox system. Implications for nitroimidazole toxicity and resistance. Mol Microbiol. 2009;72:518–36.
23. Leitsch D, Schlosser S, Burgess A, Duchêne M. Nitroimidazole drugs vary in their mode of action in the human parasite Giardia lamblia. Internat J Parasitol Drugs Drug Resis. 2012;2:166–70.
24. Williams CF, Lloyd D, Kolarich D, Alagesan K, Duchêne M, Cable J, et al. Disrupted intracellular redox balance of the diplomonad fish parasite Spironucleus vortens by 5-nitroimidazoles and garlic-derived compounds. Vet Parasitol. 2012;190:62–73.
25. Gillin FD, Diamond LS. Inhibition of clonal growth of Giardia lamblia and Entamoeba histolytica by metronidazole, quinacrine, and other antimicrobial agents. J Antimicrob Chemother. 1981;8:305–16.
26. Meloni BP, Thompson RC, Reynoldson JA, Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg. 1990;84:375–9.
27. Edlind TD, Hang TL, Chakraborty PR. Activity of the anthelmintic benzimidazoles against Giardia lamblia in vitro. J Infect Dis. 1990;162:1408–11.
28. Reynoldson JA, Thompson RC, Meloni BP. In vivo efficacy of albendazole against Giardia duodenalis in mice. Parasitol Res. 1991;77:325–8.
29. Solaymani-Mohammadi S, Genkinger JM, Loffredo CA, Singer SM. A meta-analysis of the effectiveness of albendazole compared with metronidazole as treatments for infections with Giardia duodenalis. PLoS Negl Trop Dis. 2010;4, e682.
30. di Martino L, Nocerino A, Mantovani MP. Mebendazole in giardial infections: confirmation of the failure of this treatment. Trans R Soc Trop Med Hyg. 1991;85:557–8.
31. Rousham EK. An increase in Giardia duodenalis infection among children receiving periodic Anthelmintic treatment in Bangladesh. J Trop Pediatr. 1994;40:329–33.
32. Canete R, Escobedo AA, Gonzalez ME, Almirall P. Randomized clinical study of five days apostrophe therapy with mebendazole compared to quinacrine in the treatment of symptomatic giardiasis in children. World J Gastroenterol. 2006;12:6366–70.
33. Almirall P, Escobedo AA, Ayala I, Alfonso M, Salazar Y, Cañete R, et al. Mebendazole compared with secnidazole in the treatment of adult giardiasis: a randomised, no-inferiority, open clinical trial. J Parasitol Res. 2011;2011:636857.
34. Gardner TB, Hill DR. Gardner and Hill Treatment of giardiasis. Clin Microbiol Rev. 2001;14:114–28.
35. Holberton DV, Ward AP. Isolation of the cytoskeleton from Giardia. Tubulin and a low-molecular-weight protein associated with microribbon structures. J Cell Sci. 1981;47:139–66.
36. MacDonald LM, Armson A, Thompson AR, Reynoldson JA. Characterisation of benzimidazole binding with recombinant tubulin from Giardia duodenalis, Encephalitozoon intestinalis, and Cryptosporidium parvum. Mol Biochem Parasitol. 2004;138:89–96.
37. Chavez B, Cedillo-Rivera R, Martinez-Palomo A. Giardia lamblia: ultrastructural study of the in vitro effect of benzimidazoles. J Protozool. 1992;39:510–5.
38. Gilles HM, Hoffman PS. Treatment of intestinal parasitic infections: a review of nitazoxanide. Trends Parasitol. 2002;18:95–7.
39. Adagu IS, Nolder D, Warhurst D, Rossignol JF. In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis. J Antimicrob Chemother. 2002;49:103–11.
40. Müller J, Rühle G, Müller N, Rossignol JF, Hemphill A. In vitro effects of thiazolides on Giardia lamblia WB clone C6 cultured axenically and in coculture with Caco2 cells. Antimicrob Agents Chemother. 2006;50:162–70.
41. Hoffman PS, Sisson G, Croxen MA, Welch K, Harman WD, Cremades N, et al. Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni. Antimicrob Agents Chemother. 2007;51:868–76.
42. Müller J, Wastling J, Sanderson S, Müller N, Hemphill A. A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides. Antimicrob Agents Chemother. 2007;51:1979–86.
43. Müller J, Rout S, Leitsch D, Vaithilingam J, Hehl A, Norbert MN. Comparative characterisation of two nitroreductases from Giardia lamblia as potential activators of nitro compounds. Int J Parasitol Drugs Drug Resist. 2015;5:37–43.
44. Ehsanian R, Van Waes C, Feller SM. Beyond DNA binding—a review of the potential mechanisms mediating quinacrine’s therapeutic activities in parasitic infections, inflammation, and cancers. Cell Commun Signal. 2011;9:13.
45. Upcroft JA, Campbell RW, Upcroft P. Quinacrine-resistant Giardia duodenalis. Parasitology. 1996;112:309–13.
46. Edlind TD. Susceptibility of Giardia lamblia to aminoglycoside protein synthesis inhibitors: correlation with rRNA structure. Antimicrob Agents Chemother. 1989;33:484–8.
47. Yu DC, Wang AL, Wang CC. Stable coexpression of a drug-resistance gene and a heterologous gene in an ancient parasitic protozoan Giardia lamblia. Mol Biochem Parasitol. 1996;83:81–91.
48. Boreham PF, Phillips RE, Shepherd RW. A comparison of the in-vitro activity of some 5-nitroimidazoles and other compounds against Giardia intestinalis. J Antimicrob Chemother. 1985;16:589–95.
49. Nash TE. Unraveling how Giardia infections cause disease. J Clin Invest. 2013;123:2346–7.
50. Tatsumi K, Yamada H, Yoshimura H, Kawazoe Y. Metabolism of furazolidone by milk xanthine oxidase and rat liver 9000 g supernatant: formation of a unique nitrofuran metabolite and an aminofuran derivative. Arch Biochem Biophys. 1981;208:167–74.
51. Upcroft JA, Upcroft P, Boreham PF. Drug resistance in Giardia intestinalis. Int J Parasitol. 1990;20:489–96.
52. 2O-producing NADH oxidase from the protozoan parasite Giardia duodenalis. Eur J Biochem. 1996;241:155–61.
53. Díaz EG, Montalto de Mecca M, Castro JA. Reactions of nifurtimox with critical sulfhydryl-containing biomolecules: their potential toxicological relevance. J Appl Toxicol. 2004;24:189–95.
54. Maya JD, Repetto Y, Agosín M, Ojeda JM, Tellez R, Gaule C, et al. Effects of nifurtimox and benzonidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of Trypanosoma cruzi. Mol Biochem Parasitol. 1997;86:101–6.
55. Andrews BJ, Panitescu D, Jipa GH, Vasile-Bugarin AC, Vasiliu RP, Ronnevig JR. Chemotherapy for giardiasis: randomized clinical trial of bacitracin, bacitracin zinc, and a combination of bacitracin zinc with neomycin. Am J Trop Med Hyg. 1995;52:318–21.
56. Andrews BJ, Mylvaganam H, Yule A. Sensitivity of Trichomonas vaginalis, Tritrichomonas foetus and Giardia intestinalis to bacitracin and its zinc salt in vitro. Trans R Soc Trop Med Hyg. 1994;88:704–6.
57. Smith PD, Gillin FD, Spira WM, Nash TE. Chronic giardiasis: studies on drug sensitivity, toxin production, and host immune response. Gastroenterology. 1982;83:797–803.
58. Farbey MD, Reynoldson JA, Thompson RC. In vitro drug susceptibility of 29 isolates of Giardia duodenalis from humans as assessed by an adhesion assay. Int J Parasitol. 1995;25:593–9.
59. Lemée V, Zaharia I, Nevez G, Rabodonirina M, Brasseur P, Ballet JJ, et al. Metronidazole and albendazole susceptibility of 11 clinical isolates of Giardia duodenalis from France. J Antimicrob Chemother. 2000;46:819–21.
60. Boreham PF, Phillips RE, Shepherd RW. Altered uptake of metronidazole in vitro by stocks of Giardia intestinalis with different drug sensitivities. Trans R Soc Trop Med Hyg. 1988;82:104–6.
61. Townson SM, Upcroft JA, Upcroft P. Characterisation and purification of pyruvate:ferredoxin oxidoreductase from Giardia duodenalis. Mol Biochem Parasitol. 1996;79:183–93.
62. Argüello-García R, Cruz-Soto M, Romero-Montoya L, Ortega-Pierres G. In vitro resistance to 5-nitroimidazoles and benzimidazoles in Giardia duodenalis: variability and variation in gene expression. Infect Genet Evol. 2009;9:1057–64.
63. Narikawa S. Distribution of metronidazole susceptibility factors in obligate anaerobes. J Antimirob Chemother. 1986;18:565–74.
64. Marczak R, Gorrell TE, Müller M. Hydrogenosomal ferredoxin of the anaerobic protozoon, Tritrichomonas foetus. J Biol Chem. 1983;258:12427–33.
65. Liu SM, Brown DM, O’Donoghue P, Upcroft P, Upcroft JA. Ferredoxin involvement in metronidazole resistance of Giardia duodenalis. Mol Biochem Parasitol. 2000;108:137–40.
66. Chapman A, Cammack R, Linstead D, Lloyd D. The generation of metronidazole radicals in hydrogenosomes isolated from Trichomonas vaginalis. J Gen Microbiol. 1985;131:2141–4.
67. Smith NC, Bryant C, Boreham PF. Possible roles for pyruvate:ferredoxin oxidoreductase and thiol-dependent peroxidase and reductase activities in resistance to nitroheterocyclic drugs in Giardia intestinalis. Int J Parasitol. 1988;18:991–7.
68. Ellis JE, Wingfield JM, Cole D, Boreham PF, Lloyd D. Oxygen affinities of metronidazole-resistant and -sensitive stocks of Giardia intestinalis. Int J Parasitol. 1993;23:35–9.
69. Leitsch D, Burgess AG, Dunn LA, Krauer KG, Tan K, Duchêne M, et al. Pyruvate:ferredoxin oxidoreductase and thioredoxin reductase are involved in 5-nitroimidazole activation while flavin metabolism is linked to 5-nitroimidazole resistance in Giardia lamblia. J Antimicrob Chemother. 2011;66:1756–65.
70. Dan M, Wang AL, Wang CC. Inhibition of pyruvate-ferredoxin oxidoreductase gene expression in Giardia lamblia by a virus-mediated hammerhead ribozyme. Mol Microbiol. 2000;36:447–56.
71. Dunn LA, Burgess AG, Krauer KG, Eckmann L, Vanelle P, Crozet MD, et al. A new-generation 5-nitroimidazole can induce highly metronidazole-resistant Giardia lamblia in vitro. Int J Antimicrob Agents. 2010;36:37–42.
72. Nillius D, Müller J, Müller N. Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs. J Antimicrob Chemother. 2011;66:1029–35.
73. Müller J, Schildknecht P, Müller N. Metabolism of nitro drugs metronidazole and nitazoxanide in Giardia lamblia: characterization of a novel nitroreductase (GlNR2). J Antimicrob Chemother. 2013;68:1781–9. The role of nitroreductase 2 as metronidazole resistance determinan.
74. Tejman-Yarden N, Millman M, Lauwaet T, Davids BJ, Gillin FD, Dunn L, et al. Impaired parasite attachment as fitness cost of metronidazole resistance in Giardia lamblia. Antimicrob Agents Chemother. 2011;55:4643–51.
75. Müller M, Gorrell TE. Metabolism and metronidazole uptake in Trichomonas vaginalis isolates with different metronidazole susceptibilities. Antimicrob Agents Chemother. 1983;24:667–73.
76. Yarlett N, Yarlett NC, Lloyd D. Metronidazole-resistant clinical isolates of Trichomonas vaginalis have lowered oxygen affinities. Mol Biochem Parasitol. 1986;19:111–6.
77. Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol. 1999;29:199–212.
78. Rasoloson D, Vanacova S, Tomkova E, Razga J, Hrdy I, Tachezy J, et al. Mechanisms of in vitro development of resistance to metronidazole in Trichomonas vaginalis. Microbiology. 2002;48:2467–77.
79. Leitsch D, Drinić M, Duchêne M. Down-regulation of flavin reductase and alcohol dehydrogenase-1 (ADH-1) in metronidazole-resistant isolates of Trichomonas vaginalis. Mol Biochem Parasitol. 2012;183:177–83.
80. Meingassner JG, Thurner J. Strain of Trichomonas vaginalis resistant to metronidazole and other 5-nitroimidazoles. Antimicrob Agents Chemother. 1979;16:254–7.
81. Leitsch D, Janssen BD, Kolarich D, Johnson PJ, Duchêne M. Trichomonas vaginalis Flavin reductase 1 (FR1) and its role in metronidazole resistance. Mol Microbiol. 2014;91:198–208.
82. Müller J, Ley S, Felger I, Hemphill A, Müller N. Identification of differentially expressed genes in a Giardia lamblia WB C6 clone resistant to nitazoxanide and metronidazole. J Antimicrob Chemother. 2008;62:72–82.
83. Upcroft J, Mitchell R, Chen N, Upcroft P. Albendazole resistance in Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in beta-tubulin. Microb Drug Resist. 1996;2:303–8.
84. Jiménez-Cardoso E, Eligio-García L, Cortés-Campos A, Flores-Luna A, Valencia-Mayoral P, Lozada-Chávez I. Changes in beta-giardin sequence of Giardia intestinalis sensitive and resistant to albendazole strains. Parasitol Res. 2009;105:25–33.
85. Paz-Maldonado MT, Argüello-García R, Cruz-Soto M, Mendoza-Hernández G, Ortega-Pierres G. Proteomic and transcriptional analyses of genes differentially expressed in Giardia duodenalis clones resistant to albendazole. Infect Genet Evol. 2013;15:10–7.
86. Beech RN, Skuce P, Bartley DJ, Martin RJ, Prichard RK, Gilleard JS. Anthelmintic resistance: markers for resistance, or susceptibility? Parasitology. 2011;138:160–74.
87. Docampo R, Mason RP, Mottley C, Muniz RP. Generation of free radicals induced by nifurtimox in mammalian tissues. J Biol Chem. 1981;256:10930–3.
88. Bénéré E, da Luz RA, Vermeersch M, Cos P, Maes L. A new quantitative in vitro microculture method for Giardia duodenalis trophozoites. J Microbiol Methods. 2007;71:101–6.
89. Sterk M, Müller J, Hemphill A, Müller N. Characterization of a Giardia lamblia WB C6 clone resistant to the isoflavone formononetin. Microbiology. 2007;153:4150–8.
90. Lauwaet T, Andersen Y, Van de Ven L, Eckmann L, Gillin FD. Rapid detachment of Giardia lamblia trophozoites as a mechanism of antimicrobial action of the isoflavone formononetin. J Antimicrob Chemother. 2010;65:531–4.
91. Harris JC, Plummer S, Lloyd D. Antigiardial drugs. Appl Microbiol Biotechnol. 2001;57:614–9.